Abbott Laboratories

New York Stock Exchange
Back to all articles
Somewhat Bullish +45

Abbott Laboratories $ABT Stock Position Increased by Absher Wealth ...

AI-generated analysis

📈 Absher Wealth Management increased its ABT stake by 68.9% in Q1, adding 135,846 shares to reach a total holding of 333,127 shares valued at $34.2 million.

🏦 Major institutional investors including PFA Pension ($116.58M new stake) and Danica Pension ($185.64M new stake) initiated or significantly increased positions in the fourth quarter.

💰 Abbott Laboratories reported Q1 revenue of $11.16 billion, a 7.8% year-over-year increase that beat analyst estimates by $174 million.

📊 The company posted earnings per share of $1.15, surpassing the consensus estimate of $1.14 with a net margin of 13.90% and ROE of 17.62%.

🎯 Analysts maintain a 'Moderate Buy' consensus rating with an average price target of $118.42, despite recent downward revisions from Goldman Sachs, JPMorgan, and Bank of America.

💵 The board declared a quarterly dividend of $0.63 per share payable on August 17th, providing a yield of 2.7% to shareholders of record on July 15th.

📉 Stock price action shows ABT trading at $93.97, currently below its 200-day moving average of $103.09 but above its 50-day moving average of $89.21.

👔 Insider buying activity was recorded with Director Daniel Starks purchasing 10,000 shares for $926,500 and CFO Philip Boudreau acquiring 2,200 shares for $201,300.

📅 Management provided FY 2026 EPS guidance ranging from $5.38 to $5.58, with analysts forecasting a consensus of $5.48 for the fiscal year.

🏥 Abbott operates through four main segments: diagnostics, medical devices, nutritionals, and established pharmaceuticals, serving hospitals, clinics, and direct-to-consumer channels.

Bullish Signals
  • Absher Wealth Management increased its position by 68.9% in Q1, adding 135,846 shares to a total holding of 333,127 shares valued at $34.2 million.
  • PFA Pension established a new stake worth approximately $116.58 million, while Danica Pension initiated a new position valued at roughly $185.64 million.
  • Freemont Management raised its stake by 197.2% in Q4, and Thrivent Financial boosted its position by 24.3% to own 246,586 shares.
  • Abbott Laboratories reported Q1 revenue of $11.16 billion, which represents a 7.8% increase compared to the same quarter last year.
  • The company beat analyst earnings estimates with EPS of $1.15 versus a consensus of $1.14 and revenue exceeding expectations by $174 million.
  • Management provided FY 2026 guidance for EPS between $5.38 and $5.58, indicating continued growth expectations.
  • The company declared a quarterly dividend of $0.63 per share with an annualized yield of 2.7% payable on August 17th.
  • Director Daniel J. Starks purchased 10,000 shares for $926,500, and CFO Philip P. Boudreau bought 2,200 shares for $201,300.
Risk Factors
  • Major investment banks including Goldman Sachs, JPMorgan Chase, Bank of America, and Mizuho recently lowered their price targets on ABT stock.
  • Goldman Sachs reduced its target price from $121.00 to $113.00 while maintaining a 'buy' rating in a report dated May 27th.
  • Benchmark lowered its price target from $145.00 to $120.00 and set a 'buy' rating on April 17th.
  • JPMorgan Chase dropped its price target from $123.00 to $110.00 with an 'overweight' rating in a report from April 17th.
  • Bank of America decreased its price target from $120.00 to $102.00 in a research note dated June 12th.
  • Mizuho lowered its price objective from $125.00 to $115.00 and issued a 'neutral' rating on April 17th.
  • The stock is currently trading at $93.97, which is below its 200-day moving average of $103.09.
Full Analysis
Absher Wealth Management LLC significantly increased its position in Abbott Laboratories (NYSE:ABT) by 68.9% in the first quarter, purchasing an additional 135,846 shares to own a total of 333,127 shares valued at $34.2 million. This move makes ABT the fund's 10th largest holding, representing 4.0% of its portfolio. Other major institutional investors also adjusted their stakes recently, including Freemont Management raising its position by 197.2%, PFA Pension establishing a new stake worth $116.58 million, and Danica Pension acquiring a new position valued at approximately $185.64 million. Analyst sentiment remains mixed but generally positive regarding the company's buy rating despite recent price target reductions from major banks. Goldman Sachs, Benchmark, JPMorgan Chase, Bank of America, and Mizuho all lowered their price targets in April and June, with consensus targets ranging between $102 and $145. However, the aggregate analyst consensus remains a 'Moderate Buy' with an average price target of $118.42. The stock currently trades around $93.97, trading below its 200-day moving average of $103.09 but above its 50-day moving average of $89.21. Financially, Abbott Laboratories reported strong quarterly performance with revenue of $11.16 billion, beating estimates by $174 million and growing 7.8% year-over-year. The company posted earnings per share of $1.15, slightly exceeding the consensus estimate of $1.14, while maintaining a net margin of 13.90% and a return on equity of 17.62%. Management has provided guidance for FY 2026 EPS between $5.38 and $5.58, with analysts predicting an average consensus of $5.48 for the current year. The company declared a quarterly dividend of $0.63 per share payable on August 17th to shareholders of record on July 15th, offering a yield of 2.7% and an annualized payout of $2.52. Insider activity includes Director Daniel J. Starks purchasing 10,000 shares for $926,500 and CFO Philip P. Boudreau buying 2,200 shares for $201,300. Abbott Laboratories operates globally through diagnostics, medical devices, nutritionals, and pharmaceuticals, maintaining a market capitalization of $163.69 billion with a debt-to-equity ratio of 0.56.